Design Therapeutics, Inc. (NASDAQ:DSGN) Holdings Increased by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC increased its stake in Design Therapeutics, Inc. (NASDAQ:DSGN) by 30.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,503 shares of the company’s stock after acquiring an additional 4,983 shares during the period. Tower Research Capital LLC TRC’s holdings in Design Therapeutics were worth $57,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in DSGN. Nisa Investment Advisors LLC lifted its position in Design Therapeutics by 38,433.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 11,560 shares of the company’s stock worth $31,000 after purchasing an additional 11,530 shares during the period. Federated Hermes Inc. boosted its stake in Design Therapeutics by 317.6% during the fourth quarter. Federated Hermes Inc. now owns 11,999 shares of the company’s stock valued at $32,000 after buying an additional 9,126 shares in the last quarter. SG Americas Securities LLC bought a new position in Design Therapeutics during the third quarter valued at about $47,000. Corton Capital Inc. grew its holdings in Design Therapeutics by 56.6% during the third quarter. Corton Capital Inc. now owns 27,134 shares of the company’s stock worth $64,000 after acquiring an additional 9,811 shares during the period. Finally, Algert Global LLC raised its position in Design Therapeutics by 83.3% in the third quarter. Algert Global LLC now owns 35,620 shares of the company’s stock worth $84,000 after acquiring an additional 16,190 shares in the last quarter. Institutional investors and hedge funds own 56.64% of the company’s stock.

Insider Buying and Selling at Design Therapeutics

In other Design Therapeutics news, Director John P. Schmid bought 9,156 shares of the firm’s stock in a transaction dated Friday, March 22nd. The stock was acquired at an average price of $3.62 per share, with a total value of $33,144.72. Following the completion of the transaction, the director now directly owns 9,156 shares in the company, valued at approximately $33,144.72. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, Director John P. Schmid purchased 9,156 shares of Design Therapeutics stock in a transaction dated Friday, March 22nd. The stock was acquired at an average cost of $3.62 per share, with a total value of $33,144.72. Following the completion of the transaction, the director now directly owns 9,156 shares of the company’s stock, valued at $33,144.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John P. Schmid purchased 17,809 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The shares were bought at an average price of $3.74 per share, with a total value of $66,605.66. Following the completion of the acquisition, the director now owns 26,965 shares of the company’s stock, valued at approximately $100,849.10. The disclosure for this purchase can be found here. Company insiders own 25.70% of the company’s stock.

Design Therapeutics Trading Down 1.6 %

DSGN stock traded down $0.06 during mid-day trading on Monday, reaching $3.72. 164,996 shares of the stock traded hands, compared to its average volume of 258,934. The stock’s fifty day moving average is $3.32 and its 200-day moving average is $2.69. The company has a market cap of $210.14 million, a P/E ratio of -3.10 and a beta of 1.82. Design Therapeutics, Inc. has a 52-week low of $1.94 and a 52-week high of $8.47.

Design Therapeutics (NASDAQ:DSGN) last issued its quarterly earnings results on Tuesday, March 19th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.11. Equities research analysts expect that Design Therapeutics, Inc. will post -1.26 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on DSGN. Royal Bank of Canada restated a “sector perform” rating and set a $4.00 price objective on shares of Design Therapeutics in a research report on Wednesday, March 20th. Wedbush reissued a “neutral” rating and set a $5.00 target price on shares of Design Therapeutics in a research note on Wednesday, March 20th. Seven investment analysts have rated the stock with a hold rating, According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $5.50.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.